<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Soligenix Inc — News on 6ix</title>
<link>https://6ix.com/company/soligenix-inc</link>
<description>Latest news and press releases for Soligenix Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/soligenix-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c1ff78dffbe2df11924b.webp</url>
<title>Soligenix Inc</title>
<link>https://6ix.com/company/soligenix-inc</link>
</image>
<item>
<title>Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy</title>
<link>https://6ix.com/company/soligenix-inc/news/positive-clinical-results-from-hybrytetm-comparative-study-evaluating-hybrytetm-against-valchlorr-in-the-treatment-of-cutaneous-t-cell-lymphoma-published-in-oncology-and-therapy-11</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/positive-clinical-results-from-hybrytetm-comparative-study-evaluating-hybrytetm-against-valchlorr-in-the-treatment-of-cutaneous-t-cell-lymphoma-published-in-oncology-and-therapy-11</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/</description>
</item>
<item>
<title>Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-announces-recent-accomplishments-and-year-end-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-announces-recent-accomplishments-and-year-end-2025-financial-results</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Upcoming high-impact milestones include interim analysis in Q2 2026 and top-line results in H2 2026 from HyBryte™ trialPRINCETON, N.J., March 31, 2026</description>
</item>
<item>
<title>Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-receives-orphan-drug-designation-from-the-european-commission-for-sgx945-for-the-treatment-of-behcets-disease</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-receives-orphan-drug-designation-from-the-european-commission-for-sgx945-for-the-treatment-of-behcets-disease</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-sngx-hybryte-data-to-be-presented-at-usclc-workshop-ahead-of-aad-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-sngx-hybryte-data-to-be-presented-at-usclc-workshop-ahead-of-aad-meeting</guid>
<pubDate>Tue, 24 Mar 2026 19:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - March 24, 2026 (NEWMEDIAWIRE) - Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Wor...</description>
</item>
<item>
<title>HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026</title>
<link>https://6ix.com/company/soligenix-inc/news/hybrytetm-treatment-results-to-be-presented-at-us-cutaneous-lymphoma-consortium-annual-workshop-2026</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/hybrytetm-treatment-results-to-be-presented-at-us-cutaneous-lymphoma-consortium-annual-workshop-2026</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)</description>
</item>
<item>
<title>Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-announces-hybrytetm-clinical-summary-published-in-expert-opinion-on-investigational-drugs</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-announces-hybrytetm-clinical-summary-published-in-expert-opinion-on-investigational-drugs</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-announces-sgx945-receives-promising-innovative-medicine-designation-from-the-uk-medicines-and-healthcare-products-regulatory-agency-8</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-announces-sgx945-receives-promising-innovative-medicine-designation-from-the-uk-medicines-and-healthcare-products-regulatory-agency-8</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on</description>
</item>
<item>
<title>Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-drug-designation-for-sgx945-for-the-treatment-of-behcets-disease</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-receives-positive-opinion-from-the-european-medicines-agency-on-the-request-for-orphan-drug-designation-for-sgx945-for-the-treatment-of-behcets-disease</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) provided a positive recommendation on the Company's request for orphan drug designation for dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Dise</description>
</item>
<item>
<title>Soligenix to Present at BIO Investment & Growth Summit</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-to-present-at-bio-investment-and-growth-summit</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-to-present-at-bio-investment-and-growth-summit</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President & Chief Executive Officer will deliver a corporate presentation at the BIO Investment & Growth Summit at 3:00 PM on Monday, March 2. The BIO Investment & Growth Summit, held March 2 to 3 at Eden Roc Miami Beach, in Miami Beach,</description>
</item>
<item>
<title>Soligenix Details Recent Progress and Upcoming Milestones</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-details-recent-progress-upcoming-123000520</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-details-recent-progress-upcoming-123000520</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.</description>
</item>
<item>
<title>SNGX: Positive Results for Phase 2a Trial in Psoriasis</title>
<link>https://6ix.com/company/soligenix-inc/news/sngx-positive-results-for-phase-2a-trial-in-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/sngx-positive-results-for-phase-2a-trial-in-psoriasis</guid>
<pubDate>Mon, 22 Dec 2025 09:00:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial On December 17, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. Cohort 3 consisted of four patients who were</description>
</item>
<item>
<title>Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)</title>
<link>https://6ix.com/company/soligenix-inc/news/positive-clinical-results-phase-2-123000030</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/positive-clinical-results-phase-2-123000030</guid>
<pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers</description>
</item>
<item>
<title>Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-announces-top-line-results-123000680</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-announces-top-line-results-123000680</guid>
<pubDate>Wed, 17 Dec 2025 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical</description>
</item>
<item>
<title>Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-inc-nasdaq-sngx-advancing-rare-disease-therapies-positioned-at-pivotal-crossroad</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-inc-nasdaq-sngx-advancing-rare-disease-therapies-positioned-at-pivotal-crossroad</guid>
<pubDate>Fri, 05 Dec 2025 13:30:00 GMT</pubDate>
<description>NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Breakthrough Therapies Advance as Rare Disease Burden Intens</description>
</item>
<item>
<title>SNGX: Phase 3 FLASH2 Trial Enrolls 50th Patient; Interim Analysis in 2Q26</title>
<link>https://6ix.com/company/soligenix-inc/news/sngx-phase-3-flash2-trial-enrolls-50th-patient-interim-analysis-in-2q26</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/sngx-phase-3-flash2-trial-enrolls-50th-patient-interim-analysis-in-2q26</guid>
<pubDate>Thu, 20 Nov 2025 13:06:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Enrollment in FLASH2 Trial Reaches 50; Interim Analysis in 2Q26 On November 19, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced that enrollment in the FLASH2 trial of HyBryte™ for the treatment of cutaneous T cell lymphoma (CTCL) has reached 50 participants out of a scheduled 80. Now that 50 patients are enrolled,</description>
</item>
<item>
<title>Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-achieves-enrollment-milestone-planned-123000019</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-achieves-enrollment-milestone-planned-123000019</guid>
<pubDate>Wed, 19 Nov 2025 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient confirmatory Phase 3 double-blind, placebo-controlled study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The c</description>
</item>
<item>
<title>SNGX: DMC Reports No Safety Signals for Ongoing Phase 3 Trial in CTCL; Blinded Interim Efficacy Analysis in 1H26</title>
<link>https://6ix.com/company/soligenix-inc/news/sngx-dmc-reports-no-safety-signals-for-ongoing-phase-3-trial-in-ctcl-blinded-interim-efficacy-analysis-in-1h26</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/sngx-dmc-reports-no-safety-signals-for-ongoing-phase-3-trial-in-ctcl-blinded-interim-efficacy-analysis-in-1h26</guid>
<pubDate>Mon, 10 Nov 2025 13:05:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update DMC Confirms No Safety Concerns for Ongoing Phase 3 FLASH2 Trial On October 7, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced that the Data Monitoring Committee (DMC) concluded there were no safety concerns with the ongoing Phase 3 FLASH2 Trial of HyBryte™ (SGX301 or synthetic hypericin) in the treatment of</description>
</item>
<item>
<title>Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-announces-recent-accomplishments-third-123000623</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-announces-recent-accomplishments-third-123000623</guid>
<pubDate>Fri, 07 Nov 2025 12:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2025.</description>
</item>
<item>
<title>Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-updates-united-states-medical-113000554</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-updates-united-states-medical-113000554</guid>
<pubDate>Tue, 14 Oct 2025 11:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the update of its United States (U.S.) Medical Advisory Board (MAB) for cutaneous T-cell lymphoma (CTCL) to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of HyBryte™ (synthetic hypericin) for the treatment of CTCL</description>
</item>
<item>
<title>Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma</title>
<link>https://6ix.com/company/soligenix-inc/news/soligenix-achieves-important-safety-milestone-113000712</link>
<guid isPermaLink="true">https://6ix.com/company/soligenix-inc/news/soligenix-achieves-important-safety-milestone-113000712</guid>
<pubDate>Tue, 07 Oct 2025 11:30:00 GMT</pubDate>
<description>Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its first Data Monitoring Committee (DMC) meeting for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) has concluded that there are no safety concerns with the ongoing Phase 3 study and that H</description>
</item>
</channel>
</rss>